Spots Global Cancer Trial Database for castration resistant prostate cancer
Every month we try and update this database with for castration resistant prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer | NCT01823978 | Castrate Resist... | BPX-201 vaccine... | 18 Years - | Bellicum Pharmaceuticals | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer | NCT01823978 | Castrate Resist... | BPX-201 vaccine... | 18 Years - | Bellicum Pharmaceuticals | |
| Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer | NCT02833883 | Prostate Cancer Castration Resi... | Enzalutamide CC-115 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS) | NCT01206036 | Prostatic Neopl... | Docetaxel Temsirolimus | 18 Years - | Central European Society for Anticancer Drug Research | |
| Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | NCT01646684 | Castration Resi... | SOM230 | 18 Years - | Novartis | |
| Immune Monitoring on Sipuleucel-T | NCT02237170 | Prostate Cancer | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | NCT01522443 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib mitoxantrone prednisone | 18 Years - | Exelixis | |
| OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470 | Castration Resi... | OGX-427 Prednisone | 18 Years - | British Columbia Cancer Agency | |
| A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer | NCT01337518 | Prostatic Neopl... | EZN-4176 | 18 Years - | Enzon Pharmaceuticals, Inc. | |
| Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data | NCT00578409 | Prostate Cancer | - | Memorial Sloan Kettering Cancer Center | ||
| Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | NCT03473925 | Solid Tumors Non-small Cell ... Castration Resi... Microsatellite ... | Navarixin Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer | NCT01540071 | Castration Resi... | NRX 194204 | 18 Years - | Io Therapeutics | |
| CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS) | NCT01206036 | Prostatic Neopl... | Docetaxel Temsirolimus | 18 Years - | Central European Society for Anticancer Drug Research | |
| Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | NCT01522443 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib mitoxantrone prednisone | 18 Years - | Exelixis | |
| Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | NCT03829930 | Prostate Adenoc... | Entinostat Enzalutamide | 18 Years - | George Washington University | |
| Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | NCT05502315 | Castration-resi... Metastatic Canc... | Cabozantinib Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer | NCT00953576 | Prostate Cancer | ketoconazole hydrocortisone dutasteride lapatinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer | NCT01637402 | Castration Resi... | Abiraterone Ace... Prednisone | 18 Years - | University of California, San Francisco | |
| Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | NCT02807805 | Metastatic Pros... Recurrent Prost... Stage IV Prosta... | Abiraterone Ace... Niclosamide Prednisone | 19 Years - | University of California, Davis | |
| Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer | NCT03478904 | Prostate Cancer | Enzalutamide Li... Enzalutamide Ca... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer | NCT00918385 | Prostate Cancer | Nilutamide Dasatinib | 18 Years - | Duke University | |
| Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | NCT05502315 | Castration-resi... Metastatic Canc... | Cabozantinib Nivolumab | 18 Years - | Hoosier Cancer Research Network | |
| Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer | NCT03478904 | Prostate Cancer | Enzalutamide Li... Enzalutamide Ca... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 | NCT01605227 | Prostate Cancer Castration Resi... Pain Prostatic Neopl... | cabozantinib prednisone | 18 Years - | Exelixis | |
| A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy | NCT00887458 | Prostate Cancer | Itraconazole 20... Itraconazole 30... | 18 Years - | Johns Hopkins University | |
| Treatment Satisfaction With Ra-223 in Japan | NCT03315260 | Prostatic Neopl... | Radium-223 dich... | 20 Years - | Bayer | |
| A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy | NCT00473512 | Prostatic Neopl... | Abiraterone ace... Abiraterone ace... Dexamethasone | 18 Years - | Cougar Biotechnology, Inc. | |
| A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy | NCT00887458 | Prostate Cancer | Itraconazole 20... Itraconazole 30... | 18 Years - | Johns Hopkins University | |
| OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470 | Castration Resi... | OGX-427 Prednisone | 18 Years - | British Columbia Cancer Agency | |
| Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer | NCT01692483 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Pharmaceutica | |
| OGX-427 in Castration Resistant Prostate Cancer Patients | NCT01120470 | Castration Resi... | OGX-427 Prednisone | 18 Years - | British Columbia Cancer Agency | |
| Immune Monitoring on Sipuleucel-T | NCT02237170 | Prostate Cancer | 18 Years - | Icahn School of Medicine at Mount Sinai | ||
| An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001 | NCT01664728 | Prostate Neopla... | Abiraterone ace... Glucocorticoid | 18 Years - | Janssen Research & Development, LLC | |
| Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | NCT03473925 | Solid Tumors Non-small Cell ... Castration Resi... Microsatellite ... | Navarixin Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | NCT01368003 | Adenocarcinoma ... | STA9090 STA9090 with Du... | 18 Years - | Dana-Farber Cancer Institute | |
| Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer | NCT03123978 | Metastatic Pros... Recurrent Prost... Stage IV Prosta... | Enzalutamide Niclosamide | 19 Years - | University of California, Davis | |
| Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC) | NCT00811031 | Prostate Cancer | Taxotere Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC | NCT02502994 | Castration Resi... | GEN0101 | 20 Years - 85 Years | Osaka University | |
| Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone | NCT02640534 | Cancer of the P... Prostate Cancer | Enzalutamide Metformin | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC) | NCT02384382 | Prostate Carcin... Castration Resi... | Enzalutamide | 18 Years - | Pfizer | |
| STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | NCT01368003 | Adenocarcinoma ... | STA9090 STA9090 with Du... | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
